New WHO Guidelines Address Long-Term Impact of Bacterial Meningitis

the World Health Institution (WHO) has recently released its first-ever guidelines for the diagnosis, therapy, and long-term management of bacterial meningitis, marking a meaningful step forward in the global effort to combat this devastating disease. This initiative is central to the WHO’s ambitious action plan, launched in 2020, aiming to drastically reduce the incidence and impact of bacterial meningitis by 2030.

Despite advancements in modern medicine, bacterial meningitis remains a formidable health threat, even in developed countries, frequently leading to severe, lasting disabilities and tragically, death. Globally,the burden of this disease is considerable. In 2019, approximately 2.5 million cases were reported worldwide, with young children under five years of age being disproportionately affected. Pneumococcal, meningococcal, and Klebsiella pneumoniae bacteria were responsible for nearly half of the estimated 250,000 fatalities resulting from meningitis that year. Recent data suggests that while vaccination efforts are making inroads, the disease continues to pose a significant public health challenge, notably in resource-limited settings.

The WHO’s 2020 action plan focuses on a dual strategy: eliminating meningitis epidemics in the “meningitis belt” of sub-Saharan Africa – encompassing 26 countries particularly vulnerable to outbreaks – and substantially reducing overall cases and deaths globally. the plan targets a 50% reduction in vaccine-preventable cases and a 70% decrease in meningitis-related deaths, alongside a critical focus on minimizing long-term neurological damage.

Recognizing that survival is only one aspect of addressing this disease, the WHO strategy emphasizes improving the quality of life for those who survive meningitis. This holistic approach is built upon five interconnected pillars: prevention thru vaccination, prompt and accurate diagnosis and treatment, robust surveillance systems, comprehensive management of long-term sequelae, and dedicated advocacy and support for patients and their families. A key component of this strategy was the development of globally standardized treatment guidelines, a previously missing element in the fight against bacterial meningitis.

The newly released WHO guideline addresses this gap, providing evidence-based recommendations for clinicians worldwide. The need for such a guideline is underscored by the significant disability burden associated with meningitis; it ranks as the fourth leading neurological cause of years lost to disability (Disability-Adjusted life Years or DALYs), following stroke, migraines, and dementia. This highlights the profound and lasting impact the disease has on individuals and communities.

The guideline’s creation was a collaborative effort spanning 18 months, involving 26 experts representing all six WHO regions, and supported by 46 WHO staff members. The team systematically addressed 20 key clinical questions, utilizing the GRADE system to formulate “Good Practice Statements” and “Recommendations” based on the available evidence. These comprehensive guidelines are publicly accessible on the WHO website.

Key Diagnostic Questions Addressed by the Guidelines:

When is a lumbar puncture (spinal tap) indicated? The guidelines provide clarity on the appropriate timing and circumstances for performing this crucial diagnostic procedure.
What laboratory tests are essential for confirming a diagnosis? Recommendations are made regarding the optimal use of cerebrospinal fluid analysis and other laboratory investigations.
* How should different types of meningitis be differentiated? The guidelines offer guidance on distinguishing between bacterial, viral, and other forms of meningitis to ensure targeted treatment.

These guidelines represent a crucial step towards ensuring consistent, high-quality care for individuals affected by bacterial meningitis worldwide, ultimately contributing to the WHO’s goal of conquering this devastating disease by 2030.

Navigating Acute Bacterial Meningitis: A comprehensive Guide to Diagnosis and Management

Acute bacterial meningitis represents a severe and perhaps life-threatening infection of the membranes surrounding the brain and spinal cord. Rapid diagnosis and appropriate treatment are crucial for minimizing morbidity and mortality. this article outlines the key considerations in evaluating and managing suspected cases of bacterial meningitis, drawing upon current best practices and guidelines.

Initial Assessment and the Role of Lumbar puncture

When a patient presents with symptoms suggestive of meningitis – typically fever, headache, and nuchal rigidity – prompt investigation is paramount.The cornerstone of initial diagnosis is a lumbar puncture (LP),also known as a spinal tap. This procedure allows for the collection of cerebrospinal fluid (CSF) for analysis.

The LP should be performed as quickly as possible, ideally before initiating antibiotic therapy, unless specific contraindications exist. Delaying the LP can complicate interpretation of results and potentially hinder accurate pathogen identification.

contraindications to LP include:

Known or suspected bleeding disorders.
Skin or soft tissue infection directly at or near the intended puncture site, or suspicion of a spinal epidural abscess.
Significant hemodynamic instability requiring immediate stabilization.
Signs of increased intracranial pressure (cerebral herniation).

In situations where a contraindication exists,neuroimaging (see below) should be considered before proceeding with the LP.

Analyzing Cerebrospinal Fluid: Key Diagnostic Parameters

CSF analysis provides critical information for confirming the diagnosis of bacterial meningitis and identifying the causative organism. A comprehensive CSF analysis should include:

Gram Stain: A rapid test to visualize bacteria directly, providing an immediate indication of the likely pathogen.
White Blood Cell Count (with differential): Elevated white blood cells, particularly neutrophils, are indicative of infection.
Protein Concentration: Typically elevated in bacterial meningitis due to inflammation and blood-brain barrier disruption.
Glucose Concentration: Often decreased in bacterial meningitis as bacteria consume glucose. Calculating the CSF-to-blood glucose ratio can be particularly helpful.
Lactate Levels: Measuring CSF lactate, before antibiotic administration, can be a valuable diagnostic adjunct, with elevated levels strongly suggesting bacterial infection.Recent data suggests lactate levels can be particularly useful in differentiating bacterial from viral meningitis.

Neuroimaging Considerations

While LP remains the primary diagnostic tool, cerebral imaging – typically a CT scan or MRI – may be indicated in specific circumstances.

Indications for neuroimaging include:

Presence of contraindications to LP (as listed above).
Focal neurological deficits suggesting complications like cerebral edema or abscess.
Altered mental status or seizures.
Immunocompromised patients, where atypical presentations are more common.
Suspicion of a mass lesion.

Neuroimaging can help rule out other potential causes of the patient’s symptoms and identify complications associated with meningitis.

Antibiotic Therapy: Choosing the Right Approach

Once bacterial meningitis is suspected, empirical antibiotic therapy should be initiated promptly, even before CSF results are available. The choice of antibiotic regimen depends on the patient’s age, underlying health conditions, and local antibiotic resistance patterns.

Common Pathogens and Recommended Therapies (Adults):

| Pathogen | Specific Therapy | Duration |
| ————————- | ————————————————– | ———— |
| Streptococcus pneumoniae | Ceftriaxone or cefotaxime, frequently enough with Vancomycin | 10-14 days |
| Neisseria meningitidis | Ceftriaxone | 7 days |
| Haemophilus influenzae | Ceftriaxone | 7 days |
| Listeria monocytogenes | Ampicillin or Amoxicillin | 14-21 days |

*Note: These are general guidelines and should be adjusted based on

Navigating Antibiotic Choices in Bacterial Meningitis & Common Infections

Bacterial meningitis and other serious infections demand swift and targeted antibiotic treatment. Though, the increasing prevalence of antibiotic resistance necessitates a nuanced approach to drug selection. This article outlines recommended antibiotic therapies for common causative agents, emphasizing the critical role of microbiological testing in guiding clinical decisions. It’s vital to remember that antibiotic choice must be dictated by the specific susceptibility profile of the identified pathogen.

The Importance of Accurate Diagnosis & Susceptibility Testing

Before initiating antibiotic therapy, definitive diagnosis and identification of the causative organism are paramount. While clinical presentation can suggest a likely pathogen, relying solely on symptoms is insufficient. The gold standard for pathogen characterization remains bacterial culture of cerebrospinal fluid (CSF) – when dealing with potential meningitis – coupled with antimicrobial susceptibility testing. This process determines which antibiotics are effective against the specific strain of bacteria causing the infection.

furthermore, polymerase chain reaction (PCR)-based tests performed on CSF samples are strongly recommended for detecting relevant pathogens, offering a faster diagnostic route than customary culture methods.

Guiding Antibiotic Therapy Based on Pathogen

The following provides a guide to initial antibiotic choices, categorized by common bacterial agents. Treatment durations are also indicated, though these might potentially be adjusted based on clinical response and individual patient factors.

Streptococcus pneumoniae

this bacterium is a frequent cause of bacterial meningitis, particularly in adults.

Penicillin-Susceptible Strains: Penicillin G,ampicillin,or amoxicillin are typically effective.
Penicillin-Resistant Strains: Ceftriaxone or cefotaxime are preferred alternatives.
Cephalosporin-Resistant Strains: A combination of vancomycin plus rifampicin, vancomycin plus ceftriaxone/cefotaxime, or rifampicin plus ceftriaxone/cefotaxime should be considered.

Neisseria meningitidis

Another significant cause of meningitis, especially in adolescents and young adults.

Penicillin-Susceptible Strains: Penicillin G, ampicillin, or amoxicillin are generally appropriate.
Penicillin-Resistant Strains: Ceftriaxone or cefotaxime are the recommended choices.

Haemophilus influenzae

While less common due to widespread vaccination, H. influenzae can still cause meningitis. beta-Lactamase-Negative Strains: Ampicillin or amoxicillin remain viable options.
Beta-Lactamase-Positive Strains: Ceftriaxone or cefotaxime are necessary to overcome the enzyme’s resistance mechanism.

Streptococcus agalactiae (Group B Streptococcus)

A leading cause of neonatal meningitis and sepsis.

Penicillin G, ampicillin, or amoxicillin are typically effective.

Listeria monocytogenes

This bacterium can cause meningitis, particularly in newborns, the elderly, and immunocompromised individuals.

Penicillin G,ampicillin,or amoxicillin are the standard treatment options.

Supportive Diagnostic Measures

Alongside pathogen identification, several blood tests provide valuable information to assess the severity of infection and guide management.

Blood Cultures: Obtaining blood cultures before initiating antibiotic therapy is crucial. this allows for identification of bacteremia (bacteria in the bloodstream) and further susceptibility testing. Complete Blood Count (CBC): assessing total leukocyte (white blood cell) count and differential can indicate the presence and severity of infection. Elevated white blood cell counts frequently enough signify an inflammatory response.
Inflammatory Markers: Measuring C-reactive protein (CRP) or procalcitonin can provide additional insights into the inflammatory burden and help differentiate between bacterial and viral infections.

*Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is indeed essential to consult with a qualified healthcare professional for any health concerns or before making any decisions

Navigating Acute Meningitis: A Contemporary Treatment Approach

Acute meningitis, an inflammation of the membranes surrounding the brain and spinal cord, demands swift and decisive medical intervention. Recent guidelines, particularly those from the World Health Organization (WHO), emphasize a streamlined approach focused on rapid diagnosis and treatment initiation. This article details current best practices for managing suspected cases of meningitis in both adults and children.

Prioritizing Speed: Balancing imaging and Treatment

A critical shift in meningitis management is the de-emphasis of routine cerebral imaging. While historically common, immediate brain scans are not universally recommended for individuals presenting with suspected acute meningitis. The focus should be on minimizing delays to treatment. Imaging – typically a CT or MRI scan – is reserved for specific scenarios where a space-occupying lesion (like a brain tumor or abscess) needs to be ruled out before a lumbar puncture (LP) is performed. These scenarios include:

New-onset seizures
Papilledema (swelling of the optic disc)
Focal neurological deficits (weakness on one side of the body, speech difficulties)
Altered level of consciousness
Immunocompromised state

It’s crucial to understand that delaying the administration of antibiotics to obtain imaging can significantly worsen patient outcomes. The principle is to avoid hindering the prompt start of antimicrobial therapy. According to data from the CDC, approximately 1 in 10 individuals with bacterial meningitis die, highlighting the urgency of timely intervention.

Immediate Action: The Cornerstone of Effective Management

Nonetheless of imaging considerations, the rapid transfer of patients with suspected meningitis to an appropriate healthcare facility is paramount. This ensures access to the necessary diagnostic tools and, most importantly, effective treatment.Early antimicrobial Therapy: The cornerstone of managing acute meningitis is the immediate initiation of intravenous (IV) antibiotic therapy. This should occur quickly after clinical suspicion arises, even before LP results are available.Recommended Antibiotic Regimens:

First-line: Ceftriaxone or cefotaxime are the preferred initial antibiotics. Alternative: if ceftriaxone or cefotaxime are unavailable, intravenous chloramphenicol combined with benzylpenicillin, ampicillin, or amoxicillin can be used. Listeria Coverage: For patients at increased risk of Listeria monocytogenes infection (those over 60, individuals with weakened immune systems due to medication or illness, organ transplant recipients, those with cancer, advanced HIV, diabetes, severe kidney failure, liver cirrhosis, or pregnancy), ampicillin or amoxicillin should be added to the initial regimen.

Addressing Potential Resistance: A Conditional Approach

in regions or situations where resistance to common antibiotics is a concern, the addition of vancomycin or rifampicin should be considered.This decision should be based on local antibiotic resistance patterns and epidemiological data. Such as, in areas with a high prevalence of penicillin-resistant Streptococcus pneumoniae, vancomycin provides crucial coverage.

Optimizing Treatment Duration in Non-Epidemic Settings

For patients with suspected or confirmed bacterial meningitis without identified pathogens (meaning the specific bacteria causing the infection is unknown), a 7-day course of antibiotics may be sufficient if the patient is responding well to empirical treatment.Empirical treatment refers to the initial antibiotic choice made before the causative agent is identified. However, this shorter duration is a conditional recommendation and requires careful clinical assessment.

It’s important to note that guidelines are continually evolving. the WHO’s updated guidelines (expected in 2025) represent a refinement of previous recommendations from organizations like NICE (2024), ESCMID (2016), and IDSA (2004), reflecting the latest evidence-based research. Staying abreast of these changes is vital for healthcare professionals to deliver optimal patient care.

Navigating the Complexities of Central Nervous System Infections: A Clinical Overview

Central nervous system (CNS) infections represent a significant challenge in modern medicine, demanding prompt recognition and aggressive management. These infections,encompassing conditions like meningitis and encephalitis,can lead to substantial morbidity and mortality. Early diagnosis is paramount, but can be intricate by the diverse range of clinical presentations. This article provides a detailed exploration of key indicators and treatment strategies for suspected CNS infections.

Recognizing the Warning Signs: Clinical Indicators

The initial assessment of a patient potentially suffering from a CNS infection relies heavily on identifying specific clinical features. While fever and headache are common presenting symptoms, a constellation of neurological signs often points towards a more serious underlying condition.Several neurological deficits frequently emerge in these cases. Focal neurological deficits, such as weakness on one side of the body or difficulty with speech, are consistently observed across various CNS infections.Similarly, the onset of new epileptic seizures is a critical red flag, indicating significant disruption of normal brain activity. According to the CDC, approximately 1 in 200 people will develop epilepsy at some point in their lives, and a new-onset seizure in the context of systemic illness warrants immediate investigation for CNS infection.

Beyond these, clinicians must also consider signs related to increased intracranial pressure. Papilledema,swelling of the optic disc,is a classic finding,though not always present early in the disease course.Abnormal pupil reaction to light, particularly anisocoria (unequal pupil size), can also suggest compromised neurological function. Furthermore, brain nerve failures, manifesting as difficulties with vision, facial movement, or swallowing, are frequently encountered.

The Role of Immunocompromise and Underlying Conditions

The patient’s immune status and pre-existing conditions play a crucial role in both susceptibility to and presentation of CNS infections. immune deficiency,whether congenital or acquired (like that seen in HIV/AIDS),dramatically increases the risk of opportunistic infections of the brain. Actually, individuals with compromised immune systems are up to 30 times more likely to develop CNS infections compared to immunocompetent individuals.

The presence of preceding CNS disease – a history of stroke,brain tumor,or other neurological conditions – can also predispose individuals to infection and complicate the diagnostic picture. certain risk factors increase the likelihood of developing space-occupying lesions within the CNS, which can mimic or exacerbate infectious processes.

Targeted Treatment: The Importance of Corticosteroids

Once a CNS infection is suspected, initiating treatment without delay is crucial. corticosteroids are frequently employed as adjunctive therapy, aiming to reduce inflammation and mitigate brain swelling. The general recommendation is to initiate corticosteroid treatment in all suspected cases, particularly when the etiology remains unclear.

However, there are important exceptions. During a meningococcal epidemic, the use of corticosteroids is generally not recommended, as studies have shown they may not improve outcomes and could potentially worsen the inflammatory response.

Determining when to discontinue corticosteroid therapy is equally important. Treatment should be tapered and ultimately discontinued when there is evidence of clinical improvement and the causative agent has been identified and appropriately targeted with specific antimicrobial therapy.

This overview provides a foundational understanding of the clinical indicators and initial management strategies for CNS infections. Continued research and vigilance are essential to improve diagnostic accuracy and optimize patient outcomes in the face of these challenging conditions.

Navigating Acute Bacterial Meningitis: Current Recommendations for Diagnosis & Treatment

Acute bacterial meningitis represents a significant medical emergency demanding swift recognition and intervention. This article outlines current best practices for managing suspected cases, focusing on antibiotic strategies and adjunctive therapies, considering both epidemic and non-epidemic scenarios. Globally, bacterial meningitis continues to pose a substantial health burden, with an estimated 2.8 million cases annually,resulting in over 250,000 deaths – a disproportionate number occurring in sub-Saharan Africa.

Initial Assessment & Diagnostic Considerations

Prompt diagnosis is crucial. While clinical presentation – characterized by fever, headache, stiff neck, altered mental status, and photophobia – is suggestive, definitive diagnosis requires cerebrospinal fluid (CSF) analysis obtained via lumbar puncture (LP). However, delaying treatment to obtain an LP should not occur if there is a high clinical suspicion. CSF findings typically reveal elevated white blood cell counts (primarily neutrophils), decreased glucose levels, and increased protein levels. Common causative agents include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae, though Listeria monocytogenes should be considered, particularly in neonates, the elderly, and immunocompromised individuals.

Understanding Common Pathogens:

Streptococcus pneumoniae: Remains a leading cause, especially in adults and those with underlying conditions.
Neisseria meningitidis: Frequently associated with outbreaks and epidemics, particularly in close-contact settings like college campuses or crowded living conditions.
Haemophilus influenzae: Incidence has declined significantly with widespread Hib vaccination, but remains a concern in unvaccinated populations.
Listeria monocytogenes: Frequently enough linked to foodborne illness and poses a higher risk to vulnerable populations.

Antibiotic Strategies: A Tailored Approach

Empirical antibiotic therapy – initiated before definitive pathogen identification – is the cornerstone of management. The choice of antibiotic should be guided by local resistance patterns and the patient’s age and clinical presentation.

Meningococcal Meningitis:

Epidemic Setting: A strong recommendation exists for empirical parenteral ceftriaxone administered for five days in both children and adults with suspected or probable meningococcal meningitis.
sporadic Cases: For individuals in close contact with a confirmed case, a single dose of parenteral ceftriaxone or oral ciprofloxacin is recommended as chemoprophylaxis, adjusted based on known antimicrobial resistance.
Large-Scale Epidemics: Similar chemoprophylaxis with ceftriaxone or ciprofloxacin is advised for close contacts, even in clinically suspected cases, again considering local resistance profiles.

Pneumococcal Meningitis:

Epidemic & Non-Epidemic: A conditional recommendation supports empirical parenteral antibiotic therapy for ten days in children and adults with suspected pneumococcal meningitis.

The role of Corticosteroids: Refining the Approach

the use of corticosteroids as adjunctive therapy has evolved. Current guidelines emphasize a nuanced approach:

Non-Epidemic Meningitis (LP Possible): corticosteroids should be administered with the initial antibiotic dose in suspected acute bacterial meningitis, provided there are no contraindications. This intervention aims to reduce inflammation and improve outcomes.
Non-Epidemic Meningitis (LP Not Possible): If LP is contraindicated, corticosteroids are conditionally recommended alongside antibiotics in cases of high clinical suspicion, again after excluding contraindications.
Meningococcal epidemics: Routine corticosteroid use is not recommended in suspected or probable cases during an epidemic. Pneumococcal Epidemics: Corticosteroids should be administered with the initial antibiotic dose for suspected or probable cases.

It’s critically important to note that the optimal corticosteroid dosage and duration remain areas of ongoing research.

This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is indeed essential to consult with a qualified healthcare professional for any health

Navigating Bacterial Meningitis: Updated WHO Guidelines for Optimal Patient Care

Bacterial meningitis remains a significant global health threat, demanding swift and effective management. Recent updates to the World Health Organization (WHO) guidelines aim to standardize and improve care pathways for individuals of all ages experiencing suspected or confirmed cases of this serious infection. These evidence-based recommendations, developed using a rigorous grading system, are designed for implementation worldwide, focusing on resource optimization and enhanced patient outcomes.

Rethinking Traditional Therapies: A Shift in approach

Historically, certain therapies have been routinely employed in bacterial meningitis treatment. though, the new WHO guidelines challenge some of these practices, advocating for a more nuanced and targeted approach.

Osmotic Therapy: A Cautious Stance

The guidelines now offer only a conditional recommendation against the routine use of glycerol in both pediatric and adult patients. Previously considered a method to reduce cerebral edema, current evidence doesn’t support its widespread submission in managing bacterial meningitis.

Fluid Management: Avoiding Unnecessary Restriction

Similarly, routine fluid restriction is no longer advised. Maintaining adequate hydration is crucial for overall patient health and doesn’t appear to negatively impact outcomes in bacterial meningitis cases. Instead, clinicians should focus on individualized fluid balance management based on the patient’s specific clinical presentation.

Anticonvulsant Medication: A Time-Limited Strategy

For patients experiencing acute symptomatic epileptic seizures alongside bacterial meningitis, the guidelines suggest a conditional approach to anticonvulsant therapy.if seizure-free for three months,medication can be cautiously withdrawn,minimizing prolonged exposure to potential side effects. This contrasts with older protocols that often favored extended anticonvulsant courses.

Prioritizing Long-Term Well-being: Essential Assessments & rehabilitation

Recognizing that bacterial meningitis can lead to lasting complications, the WHO guidelines place significant emphasis on comprehensive assessment and rehabilitation.

Audiological Evaluation: Protecting hearing Health

A strong recommendation is made for audiological testing in all patients – both children and adults – before hospital discharge. If immediate testing isn’t feasible, it should be completed within four weeks of leaving the hospital. Early detection of hearing loss, which affects a substantial percentage of meningitis survivors (studies suggest up to 25% experience some degree of hearing impairment), is critical for prompt intervention and rehabilitative measures like hearing aids or cochlear implants.

Neurological assessment: Identifying and Addressing Impairments

Similarly,a thorough neurological evaluation is recommended both prior to discharge and again four weeks later. This assessment should identify any neurological deficits resulting from the infection, such as cognitive impairment, motor weakness, or balance issues. Rehabilitation plans should then incorporate both pharmacological and non-pharmacological interventions tailored to the individual’s specific needs. this might include physical therapy, occupational therapy, speech therapy, and cognitive behavioral therapy.

Key Updates & Considerations for Clinical Practice

These updated guidelines represent a significant evolution in bacterial meningitis management, introducing several key innovations. For the first time, the WHO provides guidance on optimal therapy duration and criteria for discontinuing both antimicrobial and adjunctive corticosteroid treatment. this is particularly critically important in resource-limited settings where judicious use of medications is paramount.

The guidelines also differentiate between management strategies for sporadic cases versus epidemic outbreaks,acknowledging the differing epidemiological contexts. Furthermore, they address the often-overlooked long-term consequences of the disease and the importance of comprehensive rehabilitative care.

Corticosteroid Therapy: Targeted Duration & Alternatives

Dexamethasone remains the preferred corticosteroid for adjunctive therapy. Though, methylprednisone or hydrocortisone can be used as alternatives. Treatment duration is pathogen-dependent: a four-day course is recommended for Streptococcus pneumoniae or Haemophilus influenzae infections. Corticosteroid treatment can be safely discontinued earlier if a different pathogen is identified.

These updated WHO guidelines provide a robust framework for improving the care of patients with bacterial meningitis globally, emphasizing evidence-based practices, resource optimization, and a holistic approach to patient well-being.

ESCmid 2025: Decoding the WHO Bacterial Meningitis Guidelines

anticipation is building for the upcoming ESCmid (European society of clinical Microbiology and Infectious Diseases) Congress in 2025, notably regarding the presentation and discussion of the latest World Health institution (WHO) guidelines on bacterial meningitis. This potentially life-threatening infection demands a global,coordinated response,and the WHO guidelines are pivotal in shaping prevention,diagnosis,and treatment strategies worldwide. This article delves into what we can expect from these updated guidelines, focusing on the key areas likely to be addressed and their implications for healthcare professionals and public health initiatives dedicated to fighting bacterial meningitis.

The post ESCmid 2025: WHO Bacterial Meningitis Guidelines appeared first on Archynewsy.

Source link